Laboratory of Oncology, Fondazione Irccs Casa Sollievo Della Sofferenza Hospital, San Giovanni Rotondo, Italy.
Unit of Oncology, Fondazione Irccs Casa Sollievo Della Sofferenza Hospital, San Giovanni Rotondo, Italy.
Expert Opin Ther Targets. 2021 Oct;25(10):865-875. doi: 10.1080/14728222.2021.1999927. Epub 2021 Nov 18.
Fusions in neuregulin 1 () and neuregulin 2 () genes are molecular features of non-small cell lung cancer (NSCLC). These rearrangements enhance ectopic expression of the NRG/ErbB receptor-ligand and induce the triggering of downstream pathways. Evidence suggests the involvement of the NRG1/ErbB3 axis deregulation in the progression and treatment resistance of NSCLC cancer (NSCLC) and that fusions are prognostic/predictive markers for targeted therapy.
Biological and prognostic/predictive value of and fusions in NSCLC and their related cellular pathways are described and discussed. Publications in English language, peer-reviewed, high-quality international journals were identified on PubMed, as well as scientific official sites were used to update the international clinical trials progress.
and fusions should be considered as novel markers for biological therapy targeting ErbB2/ErbB3. There is evidence for the involvement of the NRG1/ErbB3 axis deregulation in cancer stem cell phenotype, tumor progression, and resistance to NSCLC therapy. Neuregulin fusions are very complex, hence many question marks must be tackled before translating these molecular lesions into clinical practice. Biology, and aggressiveness of the and fusions warrant further investigations.
神经调节蛋白 1（NRG1）和神经调节蛋白 2（NRG2）基因融合是非小细胞肺癌（NSCLC）的分子特征。这些重排增强了 NRG/ErbB 受体配体的异位表达，并诱导下游途径的触发。有证据表明，NRG1/ErbB3 轴的失调参与了 NSCLC 癌症的进展和治疗耐药性，并且融合是靶向治疗的预后/预测标志物。
描述和讨论了 NRG1 和 NRG2 融合在 NSCLC 中的生物学和预后/预测价值及其相关的细胞途径。在 PubMed 上搜索了英语同行评审的高质量国际期刊上的出版物，并使用科学官方网站更新了国际临床试验的进展。
NRG1 和 NRG2 融合应被视为针对 ErbB2/ErbB3 的生物治疗的新标志物。有证据表明，NRG1/ErbB3 轴的失调参与了癌症干细胞表型、肿瘤进展和 NSCLC 治疗耐药性。神经调节蛋白融合非常复杂，因此在将这些分子病变转化为临床实践之前，必须解决许多问题。融合的生物学和侵袭性需要进一步研究。
